Gene-editing firm Eligo Bioscience has secured $30m in a series B funding round led by Sanofi Ventures, Bpifrance and other investors, as it prepares its acne-fighting drug for clinical trials. The funding will support the development of Eligo’s EB005, a first-in-class modality topical CRISPR treatment used on moderate to severe acne vulgaris, as well as pre-IND and IND activities to get human data from an early clinical trial to treat acne vulgaris.
Ventyx Bio Cardiovascular Drug’s Phase 2 Results Set Up Talks With a Big Pharma Firm
In a placebo-controlled mid-stage study, Ventyx Biosciences’ oral NLRP3 inhibitor led to rapid and sustained reductions in levels of a protein that’s an indicator of
